Hexartan-MT 50 Tablet ER is a combination antihypertensive medication containing Telmisartan 40 mg and Metoprolol Succinate 47.5 mg in an extended-release formulation. Telmisartan, an angiotensin II receptor blocker (ARB), selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby promoting vasodilation, reducing aldosterone secretion, and lowering blood pressure. Metoprolol Succinate, a cardioselective beta-1 adrenergic receptor blocker, decreases heart rate, myocardial contractility, and cardiac output, contributing to blood pressure reduction and improved cardiac function. The extended-release formulation ensures a sustained therapeutic effect, allowing once-daily dosing and enhancing patient compliance. Hexartan-MT 50 is indicated for the management of essential hypertension, providing effective blood pressure control through dual mechanisms of action. It may also be beneficial in patients with concomitant cardiovascular conditions such as ischemic heart disease or heart failure, under appropriate medical supervision. Caution is advised in patients with bradycardia, heart block, or severe hepatic or renal impairment. Common adverse effects include dizziness, fatigue, and gastrointestinal disturbances. Regular monitoring of blood pressure, heart rate, and renal function is recommended during therapy. Hexartan-MT 50 should be prescribed and used under the guidance of a healthcare professional to optimize therapeutic outcomes and minimize risks.